Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PawPr who wrote (22)	10/23/1996 6:15:00 PM
From: Thean	of 965

I think your points have merits. Your first comment about cardiologists and their taking vacation is a good insight. I would really be interested to know if there is an established statistic. Please confirm or give pointers if possible. On your second point, if patients are getting reimbursed in the US based on FDA approved indication, then shall we expect the bulk of the sales increase in Reopro use since the halted trials originates from European sales. I do not recall if Lilly or CNTO publicly explain the geographical split of Reopro sales. Also, Salomon Ups Centocor To Strong Buy From Buy (story below) a day after Smith Barney downgraded it. Obviously the brokerage firms have quite a wide ranging opinions about Reopro and CNTO's revenue and earning short term (3-6 months). Expect to see CNTO trading in a side way pattern for the next three months or until further significant news releases. NEW YORK (Dow Jones)--Salomon Brothers Inc. analyst Meirav Chovav upgraded Centocor Inc. (CNTO) to strong buy from buy, according to a source at the firm. Further details were not immediately available.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next